Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2020

Feb 16, 2021

SELL
$162.05 - $240.27 $18.3 Million - $27.1 Million
-112,800 Reduced 71.8%
44,300 $9.73 Million
Q3 2020

Nov 16, 2020

BUY
$113.26 - $167.27 $17.8 Million - $26.3 Million
157,100 New
157,100 $26.1 Million

Others Institutions Holding MRTX

About Mirati Therapeutics, Inc.


  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Pfm Health Sciences, LP Portfolio

Follow Pfm Health Sciences, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pfm Health Sciences, LP, based on Form 13F filings with the SEC.

News

Stay updated on Pfm Health Sciences, LP with notifications on news.